Last reviewed · How we verify

Rinderon® - DP = betamethasone dipropionate

LEO Pharma · Phase 3 active Small molecule

Rinderon® - DP = betamethasone dipropionate is a Corticosteroid Small molecule drug developed by LEO Pharma. It is currently in Phase 3 development for Severe skin conditions such as psoriasis, eczema, and dermatitis.

Rinderon inhibits the body's inflammatory response by suppressing the production of various pro-inflammatory cytokines.

Rinderon inhibits the body's inflammatory response by suppressing the production of various pro-inflammatory cytokines. Used for Severe skin conditions such as psoriasis, eczema, and dermatitis.

At a glance

Generic nameRinderon® - DP = betamethasone dipropionate
SponsorLEO Pharma
Drug classCorticosteroid
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Betamethasone dipropionate, the active ingredient in Rinderon, is a synthetic corticosteroid that exerts its anti-inflammatory effects by inhibiting the transcription of inflammatory genes. This results in a decrease in the production of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, which are involved in the inflammatory response. By reducing inflammation, Rinderon helps to alleviate symptoms associated with various skin conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rinderon® - DP = betamethasone dipropionate

What is Rinderon® - DP = betamethasone dipropionate?

Rinderon® - DP = betamethasone dipropionate is a Corticosteroid drug developed by LEO Pharma, indicated for Severe skin conditions such as psoriasis, eczema, and dermatitis.

How does Rinderon® - DP = betamethasone dipropionate work?

Rinderon inhibits the body's inflammatory response by suppressing the production of various pro-inflammatory cytokines.

What is Rinderon® - DP = betamethasone dipropionate used for?

Rinderon® - DP = betamethasone dipropionate is indicated for Severe skin conditions such as psoriasis, eczema, and dermatitis.

Who makes Rinderon® - DP = betamethasone dipropionate?

Rinderon® - DP = betamethasone dipropionate is developed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).

What drug class is Rinderon® - DP = betamethasone dipropionate in?

Rinderon® - DP = betamethasone dipropionate belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Rinderon® - DP = betamethasone dipropionate in?

Rinderon® - DP = betamethasone dipropionate is in Phase 3.

What are the side effects of Rinderon® - DP = betamethasone dipropionate?

Common side effects of Rinderon® - DP = betamethasone dipropionate include Skin atrophy, Hypopigmentation, Irritation.

Related